{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=25", "query": { "condition": "Advanced Malignancy", "page": 25 }, "page_size": 10 }, "pagination": { "page": 25, "page_size": 10, "total_count": 9808, "total_pages": 981, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=26&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=24&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T06:28:09.589Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02234596", "title": "Nintedanib in Patients With Advanced Esophagogastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophagogastric Adenocarcinoma" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2014-09-04", "completion_date": "2020-04-22", "has_results": true, "last_update_posted_date": "2021-01-25", "last_synced_at": "2026-10-31T06:28:09.589Z", "location_count": 6, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02234596" }, { "nct_id": "NCT02278250", "title": "First in Human Study of M4344 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Solid Tumor" ], "interventions": [ { "name": "M4344 10 mg BIW", "type": "DRUG" }, { "name": "M4344 20 mg BIW", "type": "DRUG" }, { "name": "M4344 40 mg BIW", "type": "DRUG" }, { "name": "M4344 80 mg BIW", "type": "DRUG" }, { "name": "M4344 160 mg BIW", "type": "DRUG" }, { "name": "M4344 300 mg BIW", "type": "DRUG" }, { "name": "M4344 450 mg BIW", "type": "DRUG" }, { "name": "M4344 700 mg BIW", "type": "DRUG" }, { "name": "M4344 1050 mg BIW", "type": "DRUG" }, { "name": "M4344 1200 mg BIW", "type": "DRUG" }, { "name": "M4344 100 mg BID", "type": "DRUG" }, { "name": "M4344 150 mg QD", "type": "DRUG" }, { "name": "M4344 250 mg QD", "type": "DRUG" }, { "name": "M4344 350 mg QD", "type": "DRUG" }, { "name": "M4344 400 mg", "type": "DRUG" }, { "name": "M4344 500 mg", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2015-01-26", "completion_date": "2021-09-24", "has_results": true, "last_update_posted_date": "2023-03-16", "last_synced_at": "2026-10-31T06:28:09.589Z", "location_count": 8, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • St Louis, Missouri + 4 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02278250" }, { "nct_id": "NCT02954523", "title": "Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "EGFR Gene Mutation", "Nonsmall Cell Lung Cancer" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chul Kim", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2016-10", "completion_date": "2023-03-03", "has_results": true, "last_update_posted_date": "2024-07-05", "last_synced_at": "2026-10-31T06:28:09.589Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Hackensack, New Jersey", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02954523" }, { "nct_id": "NCT00005023", "title": "Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Lung Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "HER-2/neu peptide vaccine", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "1999-03", "completion_date": "2001-01", "has_results": false, "last_update_posted_date": "2017-11-30", "last_synced_at": "2026-10-31T06:28:09.589Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005023" }, { "nct_id": "NCT05304962", "title": "FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "RGT-419B", "type": "DRUG" }, { "name": "RGT-419B in combination with hormonal therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regor Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2022-03-04", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-31T06:28:09.589Z", "location_count": 8, "location_summary": "La Jolla, California • Los Angeles, California • Port Saint Lucie, Florida + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05304962" }, { "nct_id": "NCT01685346", "title": "Biofeedback Training in Patients With Advanced Lung Cancer - A Pilot Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Advanced (Stage IV) Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "biofeedback-mediated stress management (BFSM)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2012-10", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2015-07-10", "last_synced_at": "2026-10-31T06:28:09.589Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01685346" }, { "nct_id": "NCT00474383", "title": "An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Neoplasms" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Glucocorticoid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cougar Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 47, "start_date": "2006-11", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2014-05-12", "last_synced_at": "2026-10-31T06:28:09.589Z", "location_count": 2, "location_summary": "San Francisco, California • New York, New York", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00474383" }, { "nct_id": "NCT02623959", "title": "Indwelling Pleural Catheter With Either Doxycycline or Saline at Day 7 for Pleurodesis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Advanced Cancers", "Malignant Pleural Effusions" ], "interventions": [ { "name": "Questionnaires", "type": "BEHAVIORAL" }, { "name": "Fentanyl Patch", "type": "DRUG" }, { "name": "Fentanyl (IV)", "type": "DRUG" }, { "name": "Saline", "type": "OTHER" }, { "name": "Doxycycline", "type": "DRUG" }, { "name": "Phone Calls", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL", "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2016-04-27", "completion_date": "2017-05-23", "has_results": true, "last_update_posted_date": "2019-08-07", "last_synced_at": "2026-10-31T06:28:09.589Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02623959" }, { "nct_id": "NCT05608369", "title": "Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HPV-Related Squamous Cell Carcinoma", "Squamous Cell Carcinoma of the Oral Cavity", "Squamous Cell Carcinoma of the Larynx", "Squamous Cell Carcinoma of the Oropharynx", "Squamous Cell Carcinoma of the Hypopharynx" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2025-06-01", "completion_date": "2026-02-01", "has_results": false, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-10-31T06:28:09.589Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05608369" }, { "nct_id": "NCT00343083", "title": "Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer of Head and Neck" ], "interventions": [ { "name": "Erbitux, Paclitaxel & Carboplatin", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2004-12", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2019-08-19", "last_synced_at": "2026-10-31T06:28:09.589Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00343083" } ] }